cjc-1295 ipamorelin 10mg blend dosage + cjc-1295 ipamorelin blend 10mg composition
Description
CJC-1295 no DAC & Ipamorelin with Alcohol Safety Direct Evidence No published clinical trial has directly tested CJC-1295 and Ipamorelin efficacy in the presence of acute alcohol consumption
Potential risks include breast tenderness, headaches, slight increase in breast cancer risk with prolonged synthetic progestin use (not seen with micronized progesterone), blood clot risk with oral estrogen (not transdermal), and gallbladder disease risk with oral estrogen
All source data behind each graph are shown in Supplementary Data 1
& Pearson, P
